Pancreas Cancer Clinical Trial
Official title:
Early Recovery Outcomes After Standardized Fast-track Whipples Procedure
Today the Whipple procedure is the preferred operation for malignancy in the pancreas. In
abdominal surgery this procedure is known for its high surgical stress-response in the
patient, which has been attempted to be resolved with the introduction of preoperative
high-dose steroids and goal-directed fluid therapy (GDT). Despite this effort, complications
still occur regularly (30%) in the first weeks after the operation here at Rigshospitalet.
Therefore there is still a challenge in the patients who have undergone the Whipple procedure
in the acute postoperative phase. This shows in for example at Rigshospitalet, where 50% of
the patients continue to be in the need of vasoactive medication the morning after the
operation.
Nevertheless, no studies have in detail described the acute (<24h) postoperative phase. There
is also an importance in the fact that there is often no description or control over other
important factors, for example medicine with influence on the circulatory system, fluid
treatment and response to this etc..
The purpose of this study is to investigate what issues or complications, in particular those
of circulatory matter that occurs in this particular group of patients 24 hours after the
operation. Furthermore there is lacking a description of which cause-response- link there can
be between early and later (30 days) complications, as well as when each of these
complications occur. Therefore, there will also be collected data on complications within the
first 30 days after the operation for the purpose of a later secondary publication with the
same authors.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05435053 -
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Recruiting |
NCT06065891 -
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05048524 -
Peri-operative SLOG for Localized Pancreatic Cancer
|
Phase 2 | |
| Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
| Recruiting |
NCT05501379 -
Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
|
||
| Recruiting |
NCT04851106 -
Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.
|
||
| Enrolling by invitation |
NCT04466189 -
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
|
||
| Not yet recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
| Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT01411072 -
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
|
N/A | |
| Active, not recruiting |
NCT01448668 -
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
|
N/A | |
| Completed |
NCT01155882 -
Registry Study - Whipple at the Splenic Artery
|
||
| Recruiting |
NCT04970056 -
Pancreatic Cancer Early Detection Consortium
|
||
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 |